How Important Are T-Cell Chemokines in Chronic Manifestations of Lyme Disease?

Researchers continue to investigate why some patients experience persistent symptoms after treatment for Lyme disease. One area of growing interest involves T-cell chemokines—immune signaling proteins that may contribute to prolonged inflammation and symptom persistence.

T-cell chemokines are signaling proteins that help direct immune cells to sites of infection and inflammation. Researchers have proposed that elevated chemokines—including CCL19, CXCL9, and CXCL10—may help explain why some patients continue to experience chronic manifestations after Lyme disease treatment.

For a broader discussion of mechanisms behind persistent symptoms, visit Persistent Lyme Disease Mechanisms.

Why Researchers Are Studying Chemokines

Chemokines help coordinate immune responses by attracting inflammatory cells into tissues. Persistent elevation of certain chemokines may reflect ongoing immune activation even after antibiotic treatment.

This research is important because chronic manifestations of Lyme disease often include fatigue, cognitive difficulties, musculoskeletal pain, and neurologic symptoms that are not fully explained by standard testing alone.

Which T-Cell Chemokines Have Been Linked to Persistent Symptoms?

Several chemokines have been investigated in Lyme disease patients with persistent symptoms and inflammatory manifestations.

• CCL19: associated with persistent symptoms following treatment and proposed as a biomarker candidate.
• CXCL9: associated with inflammatory responses in Lyme arthritis and antibiotic-refractory disease.
• CXCL10: linked to recruitment of inflammatory T cells and ongoing immune activation.

These findings support the theory that immune dysregulation may continue even after treatment in some patients.

CCL19 and Persistent Lyme Symptoms

CCL19 has attracted attention because elevated levels have been associated with persistent symptoms after treatment. Researchers have proposed that this chemokine may identify patients at increased risk for prolonged recovery.

Patients with persistent symptoms are discussed further in our guide to post-treatment Lyme disease syndrome.

Chemokines and Lyme Arthritis

Research on Lyme arthritis has demonstrated particularly strong inflammatory chemokine responses. Studies examining synovial tissue and joint fluid have found elevated CXCL9 and CXCL10 levels in patients with antibiotic-refractory Lyme arthritis.

These findings suggest that immune activation may persist even when evidence of active infection becomes more difficult to demonstrate.

Learn more about inflammatory manifestations in persistent Lyme disease symptoms.

Are Chemokines Ready for Routine Clinical Use?

Although chemokine research is promising, these biomarkers are not routinely used in everyday clinical practice. Larger studies are needed to determine how accurately chemokines predict persistent symptoms or guide treatment decisions.

At present, chemokine testing remains primarily a research tool rather than a standard clinical test.

Frequently Asked Questions

What are T-cell chemokines?

T-cell chemokines are immune signaling proteins that recruit inflammatory cells to tissues during infection and inflammation.

Can chemokines explain persistent Lyme symptoms?

Researchers have proposed that elevated chemokines such as CCL19, CXCL9, and CXCL10 may contribute to persistent inflammation in some patients.

Is CCL19 used clinically for Lyme disease?

CCL19 remains investigational and is not routinely used in standard clinical practice.

Are chemokines associated with Lyme arthritis?

Studies have found elevated inflammatory chemokines in patients with antibiotic-refractory Lyme arthritis, particularly CXCL9 and CXCL10.

Clinical Perspective

Chemokine research offers one possible explanation for why some patients continue to experience symptoms despite standard treatment. Persistent immune activation may contribute to ongoing inflammation in subsets of patients, although many questions remain unanswered.

Clinical Takeaway

T-cell chemokines such as CCL19, CXCL9, and CXCL10 may provide insight into chronic manifestations of Lyme disease and persistent inflammation. While these biomarkers are not ready for routine clinical use, they continue to shape research into why recovery differs from patient to patient.

Related Articles

Learn more about related topics:

• Persistent Lyme Disease Mechanisms
• Post-Treatment Lyme Disease Syndrome
• Persistent Lyme Disease Symptoms
• Lyme Arthritis

References

1. 1. Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a Chemokine Risk Factor for Post-Treatment Lyme Disease Syndrome: A Prospective Clinical Cohort Study. Clin Vaccine Immunol. 2013;20(12):1886–1891.
   2. Shin JJ, Glickstein LJ, Steere AC. High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory Lyme arthritis. Arthritis Rheum. 2007;56(4):1325–1335.
   3. Shin JJ, Strle K, Glickstein LJ, Luster AD, Steere AC. Borrelia burgdorferi stimulation of chemokine secretion by cells of monocyte lineage in patients with Lyme arthritis. Arthritis Res Ther. 2010;12(5):R168.
   4. Wester KE, Nwokeabia BC, Hassan R, Dunphy T, Osondu M, Wonders C, Khaja M. What Makes It Tick: Exploring the Mechanisms of Post-treatment Lyme Disease Syndrome. Cureus. 2024;16(7):e64987.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention